Interlaboratory concordance of PD‐L1 immunohistochemistry for non‐small‐cell lung cancer
暂无分享,去创建一个
I. Petersen | M. Tiemann | A. Warth | W. Weichert | P. Schirmacher | K. Schwamborn | M. Dietel | T. Henkel | J. Wolf | F. Lasitschka | S. Reu | J. Rüschoff | R. Büttner | B. Jasani | G. Baretton | H. Schildhaus | T. Kirchner | L. Heukamp | U. Sommer | K. Jöhrens | O. Stoss | A. Scheel | R. Diezko | Gudrun Baenfer
[1] C. Copie-Bergman,et al. Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms , 2017, PloS one.
[2] J. Taube,et al. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer , 2017, JAMA oncology.
[3] R. Røge,et al. Accurate PD-L1 Protocols for Non–Small Cell Lung Cancer can be Developed for Automated Staining Platforms With Clone 22C3 , 2017, Applied immunohistochemistry & molecular morphology : AIMM.
[4] D. Rimm,et al. A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1 , 2017, JAMA oncology.
[5] F. Hirsch,et al. PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[6] Carlos Barrios,et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.
[7] C. Boeckx,et al. Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system , 2017, Histopathology.
[8] D. Rimm,et al. Quantitative and Pathologist-Read comparison of the Heterogeneity of Programmed Death-Ligand 1(PD-L1) expression in Non-Small Cell Lung Cancer , 2016, Modern Pathology.
[9] S. Lantuejoul,et al. PL04a.04: Multicentric French Harmonization Study for PD-L1 IHC Testing in NSCLC , 2017 .
[10] Clive R. Taylor,et al. Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 1 Fit-for-Purpose Approach to Classification of Clinical Immunohistochemistry Biomarkers , 2017, Applied immunohistochemistry & molecular morphology : AIMM.
[11] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[12] M. Tiemann,et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas , 2016, Modern Pathology.
[13] R. Booton,et al. PD‐L1 testing for lung cancer in the UK: recognizing the challenges for implementation , 2016, Histopathology.
[14] Antoni Ribas,et al. The “cancer immunogram” , 2016, Science.
[15] Keunchil Park,et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.
[16] J. Taube,et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.
[17] Y. Shentu,et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.
[18] L. Zitvogel,et al. Microbiome and Anticancer Immunosurveillance , 2016, Cell.
[19] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[20] Jorge Sabbaga,et al. Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice , 2015, Oncotarget.
[21] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[22] J. Lunceford,et al. Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.
[23] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[24] T. Nielsen,et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] A. Ruifrok,et al. Quantification of histochemical staining by color deconvolution. , 2001, Analytical and quantitative cytology and histology.